Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Biogerontology ; 19(2): 109-120, 2018 04.
Artigo em Inglês | MEDLINE | ID: mdl-29255944

RESUMO

Cytokinins are phytohormones that are involved in many processes in plants, including growth, differentiation and leaf senescence. However, they also have various activities in animals. For example, kinetin and trans-zeatin can reduce levels of several aging markers in human fibroblasts. Kinetin can also protect mice against oxidative and glyoxidative stress, and prolong fruit flies' lifespan. Additionally, several cytokinins are currently used in cosmetics. To extend knowledge of the breadth of cytokinins' activities, we examined effects of natural cytokinin bases on the model nematode Caenorhabditis elegans. We found that kinetin, para-topolin and meta-topolin prolonged the lifespan of C. elegans. Kinetin also protected the organism against oxidative and heat stress. Furthermore, our results suggest that presence of reactive oxygen species, but not DAF-16 (the main effector of the insulin/insulin-like growth factor signaling pathway), is required for the beneficial effects of kinetin. Ultra-high performance liquid chromatography-tandem mass spectrometric analysis showed that kinetin is unlikely to occur naturally in C. elegans, but the worm efficiently absorbs and metabolizes it into kinetin riboside and kinetin riboside-5'-monophosphate.


Assuntos
Caenorhabditis elegans/efeitos dos fármacos , Citocininas/farmacologia , Longevidade/efeitos dos fármacos , Reguladores de Crescimento de Plantas/farmacologia , Animais , Caenorhabditis elegans/genética , Caenorhabditis elegans/fisiologia , Proteínas de Caenorhabditis elegans/genética , Proteínas de Caenorhabditis elegans/metabolismo , Citocininas/farmacocinética , Fatores de Transcrição Forkhead/genética , Fatores de Transcrição Forkhead/metabolismo , Resposta ao Choque Térmico/efeitos dos fármacos , Insulina/metabolismo , Cinetina/farmacocinética , Cinetina/farmacologia , Longevidade/fisiologia , Mutação , Estresse Oxidativo/efeitos dos fármacos , Reguladores de Crescimento de Plantas/farmacocinética , Espécies Reativas de Oxigênio/metabolismo , Transdução de Sinais/efeitos dos fármacos , Termotolerância/efeitos dos fármacos
2.
J Pharm Sci ; 106(6): 1578-1585, 2017 06.
Artigo em Inglês | MEDLINE | ID: mdl-28259765

RESUMO

Complex coacervates of cationic polymers and anionic surfactants, which are produced spontaneously during the use of rinse-off formulations, represent an important delivery vehicle for topical agents to the skin surface and appendages. In this study, an artificial sebum-loaded cell culture insert method for determining the sebum diffusion properties of topical agents was optimized for in vitro release testing. This method was subsequently used to evaluate the transport kinetics of a model compound, kinetin, released from semi-solid coacervate formulations into sebum. Coacervate compositions were prepared with cationic-hydroxyethyl cellulose dodecyl sulfate (cat-HECDS), sodium dodecyl sulfate (NaDS), and water. Tested compositions ranged from 90 to 50 wt% water and had a cat-HECDS to NaDS wt% ratio of 2:1, 1:1, or 1:2, mimicking the in vivo hydration range and relative excess surfactant content expected from commercial rinse-off formulations. Steady-state flux of the model compound from each coacervate composition was found to vary with water content of the composition. When flux was plotted versus [(cat-HECDS:NaDS) × (1 - weight fraction water)]-1, a strong linear correlation (R2 = 0.89) emerged. The in vitro release testing method proved capable of discriminating between clinically relevant differences in transport kinetics from different coacervate formulations using a practical sample size.


Assuntos
Celulose/análogos & derivados , Portadores de Fármacos/química , Cinetina/administração & dosagem , Sebo/metabolismo , Administração Tópica , Cátions/química , Celulose/química , Humanos , Cinética , Cinetina/farmacocinética , Permeabilidade , Absorção Cutânea , Dodecilsulfato de Sódio/química
3.
J Biomed Nanotechnol ; 11(10): 1734-46, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26502637

RESUMO

N-6-furfuryl adenine (N6FA) also known as "kinetin" is a biologically active natural phytochemical. It belongs to the category of cytokinins, the natural plant growth hormones that promote cell division and play role in cell differentiation. Overall, N6FA aids in increasing the plant's life span. Human cells also contain.small quantities of N6FA. Scientists are trying to understand its function in humans. N6FA is being investigated for its properties such as antiplatelet, antioxidant, antiproliferative and anti-aging effects on human cells. The aim of the present investigation was to prepare solid lipid nanoparticle (SLN) based topical formulations of N6FA and to evaluate its efficacy against ultraviolet (UV) radiation induced skin photodamage. SLNs were prepared by hot microemulsion technique and optimized for the type and concentration of lipid and surfactant(s). The optimized SLN formulation was characterized in terms of particle size, drug entrapment efficiency, zeta potential and pH; evaluated for stability, spreadability, ex-vivo skin permeation and photoprotective effects against UV induced skin damage. The cumulative amount of drug permeated through mice skin using SLNs was 3 folds higher than from conventional cream base. The results of biochemical and histopathological investigations of skin treated with N6FA loaded SLNs clearly demonstrated the efficacy of optimized formulation in preventing photodamage (lesions, ulcers and changes in skin integrity) due to chronic UV exposure. The effects were comparable with widely used marketed formulation, Garnier wrinkle lift anti-aging cream. Results suggested that N6FA incorporated into SLNs may provide therapeutic as well as cosmeceutical benefits.


Assuntos
Cinetina/administração & dosagem , Lipossomos/química , Nanocápsulas/química , Absorção Cutânea/fisiologia , Envelhecimento da Pele/efeitos dos fármacos , Pele/metabolismo , Animais , Difusão , Composição de Medicamentos/métodos , Feminino , Técnicas In Vitro , Cinetina/química , Cinetina/farmacocinética , Lipossomos/ultraestrutura , Masculino , Camundongos , Nanocápsulas/ultraestrutura , Tamanho da Partícula , Ratos Wistar , Pele/efeitos dos fármacos , Envelhecimento da Pele/fisiologia , Creme para a Pele/administração & dosagem , Creme para a Pele/síntese química , Creme para a Pele/farmacologia , Resultado do Tratamento
4.
Pediatr Res ; 70(5): 480-3, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21775922

RESUMO

Familial dysautonomia (FD) is caused by an intronic splice mutation in the IKBKAP gene that leads to partial skipping of exon 20 and tissue-specific reduction in I-κ-B kinase complex-associated protein/elongation protein 1 (IKAP/ELP-1) expression. Kinetin (6-furfurylaminopurine) has been shown to improve splicing and increase WT IKBKAP mRNA and IKAP protein expression in FD cell lines and carriers. To determine whether oral kinetin treatment could alter mRNA splicing in FD subjects and was tolerable, we administered kinetin to eight FD individuals homozygous for the splice mutation. Subjects received 23.5 mg/Kg/d for 28 d. An increase in WT IKBKAP mRNA expression in leukocytes was noted after 8 d in six of eight individuals; after 28 d, the mean increase compared with baseline was significant (p = 0.002). We have demonstrated that kinetin is tolerable in this medically fragile population. Not only did kinetin produce the desired effect on splicing in FD patients but also that effect seems to improve with time despite lack of dose change. This is the first report of a drug that produces in vivo mRNA splicing changes in individuals with FD and supports future long-term trials to determine whether kinetin will prove therapeutic in FD patients.


Assuntos
Proteínas de Transporte/metabolismo , Disautonomia Familiar/fisiopatologia , Regulação da Expressão Gênica/efeitos dos fármacos , Cinetina/farmacologia , Splicing de RNA/efeitos dos fármacos , RNA Mensageiro/metabolismo , Administração Oral , Adulto , Análise de Variância , Área Sob a Curva , Proteínas de Transporte/genética , Disautonomia Familiar/genética , Feminino , Humanos , Cinetina/administração & dosagem , Cinetina/sangue , Cinetina/farmacocinética , Masculino , New York , Splicing de RNA/fisiologia , Fatores de Elongação da Transcrição
5.
Pediatr Res ; 65(3): 341-6, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19033881

RESUMO

Familial dysautonomia (FD) is caused by an intronic splice mutation in the IkappaB kinase-associated protein gene (IKBKAP) that leads to partial skipping of exon 20 and tissue-specific reduction of IkappaB kinase-associated protein/elongator protein 1 (IKAP/ELP-1 protein). Kinetin increases IKBKAP mRNA and protein expression in FD cell lines. To determine whether oral kinetin alters IKBKAP splicing in vivo, we administered kinetin to 29 healthy carriers of the major FD mutation for 8 d. Adverse effects, kinetin, and IKBKAP mRNA levels were monitored. In the highest dosing cohorts (23.5 mg/kg/d), the target plasma kinetin level was achieved in 91% of subjects at 2 h. After 8 d, IKBKAP mRNA expression in leukocytes increased as kinetin levels increased. There is a linear association between log plasma kinetin level and corresponding log change from baseline in IKBKAP mRNA expression that allows estimation of IKBKAP mRNA levels because of kinetin ingestion. Adverse effects were transient and mild. This is the first report of in vivo IKBKAP splicing modification and strongly suggests kinetin's therapeutic potential in FD and perhaps in other splicing disorders. Furthermore, our findings support our hypothesis that treatments, which target a particular splicing mutation, can be successfully developed.


Assuntos
Processamento Alternativo/genética , Proteínas de Transporte/genética , Disautonomia Familiar/genética , Regulação da Expressão Gênica/efeitos dos fármacos , Heterozigoto , Cinetina/farmacologia , RNA Mensageiro/metabolismo , Adulto , Processamento Alternativo/efeitos dos fármacos , Proteínas de Transporte/metabolismo , Relação Dose-Resposta a Droga , Disautonomia Familiar/tratamento farmacológico , Feminino , Humanos , Cinetina/sangue , Cinetina/farmacocinética , Masculino , Mutação/genética , RNA Mensageiro/genética , Estatísticas não Paramétricas , Fatores de Elongação da Transcrição
6.
Clin Cancer Res ; 11(13): 4875-87, 2005 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-16000586

RESUMO

PURPOSE: To investigate pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine, and CYC202 (R-roscovitine; seliciclib) in the HCT116 human colon carcinoma model. EXPERIMENTAL DESIGN: The in vitro activity of the agents was determined in a human tumor panel using the sulforhodamine B assay. The concentration and time dependence was established in HCT116 cells. Molecular biomarkers, including RB phosphorylation and cyclin expression, were assessed by Western blotting. Pharmacokinetic properties were characterized in mice following analysis by liquid chromatography-tandem mass spectrometry. Based on these studies, a dosing regimen was developed for CYC202 that allowed therapeutic exposures in the HCT116 tumor xenograft. RESULTS: The antitumor potency of the agents in vitro was in the order olomoucine (IC50, 56 micromol/L) < bohemine (IC50, 27 micromol/L) < CYC202 (IC50, 15 micromol/L), corresponding to their activities as cyclin-dependent kinase inhibitors. Antitumor activity increased with exposure time up to 16 hours. The agents caused inhibition of RB and RNA polymerase II phosphorylation and depletion of cyclins. They exhibited relatively rapid clearance following administration to mice. CYC202 displayed the slowest clearance from plasma and the highest tumor uptake, with oral bioavailability of 86%. Oral dosing of CYC202 gave active concentrations in the tumor, modulation of pharmacodynamic markers, and inhibition of tumor growth. CONCLUSIONS: CYC202 showed therapeutic activity on human cancer cell lines in vitro and on xenografts. Pharmacodynamic markers are altered in vitro and in vivo, consistent with the inhibition of cyclin-dependent kinases. Such markers may be potentially useful in the clinical development of CYC202 and other cyclin-dependent kinase inhibitors.


Assuntos
Quinases Ciclina-Dependentes/antagonistas & inibidores , Inibidores Enzimáticos/farmacologia , Inibidores Enzimáticos/farmacocinética , Neoplasias Experimentais/metabolismo , Animais , Área Sob a Curva , Western Blotting , Proteína Quinase CDC2/antagonistas & inibidores , Proteína Quinase CDC2/metabolismo , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Quinases Ciclina-Dependentes/metabolismo , Feminino , Células HCT116 , Humanos , Concentração Inibidora 50 , Cinetina/farmacocinética , Cinetina/farmacologia , Dose Máxima Tolerável , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Neoplasias Experimentais/patologia , Fosforilação/efeitos dos fármacos , Purinas/farmacocinética , Purinas/farmacologia , Proteínas Recombinantes/antagonistas & inibidores , Proteínas Recombinantes/metabolismo , Proteína do Retinoblastoma/metabolismo , Roscovitina , Fatores de Tempo , Distribuição Tecidual , Ensaios Antitumorais Modelo de Xenoenxerto
7.
PGRSA Q ; 20(4): 189-99, 1992.
Artigo em Inglês | MEDLINE | ID: mdl-11537753

RESUMO

Calli were induced either from excised rice embryos or from whole seeds in the presence of 1 to 5 mg l-1 NAA. After 12 days of culture, calli were induced only from excised rice embryos. We found that excised embryos accumulated NAA up to 6 times higher concentration than did whole seeds. In the presence of 1 to 5 mg l-1 NAA and 2 to 10 mg l-1 kinetin, chlorophyllous calli were induced from excised rice embryos. Chlorophyll contents in the callus tissue increased with increasing kinetin concentration while percent callus induction decreased. The total chlorophyll content was linearly correlated with the ratio of kinetin to NAA in the medium.


Assuntos
Cinetina/farmacocinética , Ácidos Naftalenoacéticos/farmacocinética , Oryza/fisiologia , Reguladores de Crescimento de Plantas/farmacocinética , Sementes/crescimento & desenvolvimento , Divisão Celular/fisiologia , Células Cultivadas , Clorofila/biossíntese , Cromatografia em Camada Fina , Meios de Cultivo Condicionados/análise , Meios de Cultivo Condicionados/farmacologia , Oryza/efeitos dos fármacos , Oryza/crescimento & desenvolvimento , Sementes/citologia , Sementes/efeitos dos fármacos , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA